Out of the tested 14 derivatives, four (1a, 1b, 1c, and 1e) showed pronounced growth inhibitory effects both in p53-wildtype (HepG2) and p53-mutated (Huh-7) hepatoma cells with IC50 values in the (sub-)micromolar range, thereby being below that of the clinically relevant inhibitor sorafenib, which was used as a reference (Table 1). This evidence concerns the gene TP53 and hepatocellular carcinoma.